Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
According to researchers, abnormalities in the skin barrier and in the immune system that characterize atopic dermatitis can be reversed by drugs that narrowly target the immune signaling proteins interleukin (IL)-4 and -13.
The human monoclonal antibody dupilumab has shown promising results in treating moderate-to-severe atopic dermatitis in a series of phase 2 studies as both monotherapy and in combination with topical glucocorticoids.